Table 3.
1-, 3-, and 5-year overall survival rate and median survival time after reorganization according to tumor deposits and lymph node stage
| III stage | 1-year survival (%) | 3-year survival (%) | 5-year survival (%) | mOS (months) |
|---|---|---|---|---|
| pN0 | ||||
| N0TDs ≤ 4 | 93.46 | 80.93 | 67.77 | NA (101, NA) |
| N0TDs > 4 | 88.89 | 51.85 | 41.48 | 43 (26, NA) |
| pN1a | ||||
| N1aTDs- | 94.80 | 85.46 | 77.56 | NA |
| N1aTDs ≤ 4 | 92.47 | 76.83 | 66.39 | NA (100, NA) |
| N1aTDs > 4 | 90.48 | 61.90 | 37.83 | 50 (25, NA) |
| pN1b | ||||
| N1bTDs- | 93.83 | 80.87 | 70.89 | NA |
| N1bTDs ≤ 4 | 91.93 | 73.55 | 58.90 | 82 (66, NA) |
| N1bTDs > 4 | 91.67 | 79.05 | 59.08 | 64 (52, NA) |
| pN2a | ||||
| N2aTDs- | 93.63 | 76.48 | 65.17 | NA (102, NA) |
| N2aTDs ≤ 4 | 91.87 | 70.09 | 54.42 | 73 (58, NA) |
| N2aTDs > 4 | 76.27 | 43.49 | 31.81 | 33 (29, 51) |
| pN2b | ||||
| N2bTDs- | 86.88 | 64.25 | 52.24 | 65 (58, 73) |
| N2bTDs ≤ 4 | 86.12 | 60.59 | 47.30 | 53 (44, NA) |
| N2bTDs > 4 | 77.62 | 51.07 | 28.16 | 37 (24, 47) |